Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.50 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.47 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.46 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.46 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.46 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MYOC | Q99972 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12664955 | 0.88 | RAB9A (0.48) | TTBK1TTBK2EGFRERBB2RAB9A | |
| SCHEMBL3166433 | 0.88 | NPC1 (0.60) | TTBK1TTBK2EGFRRAB9ANPC1 | |
| SCHEMBL1894480 | 0.88 | MEN1 (0.52) | TTBK1TTBK2EGFRERBB2RAB9A | |
| SCHEMBL3166827 | 0.87 | EGFR (0.49) | CRHBPCRHR2EGFRERBB2RAB9A | |
| SCHEMBL1898323 | 0.85 | RAB9A (0.46) | TTBK1TTBK2EGFRERBB2RAB9A | |
| SCHEMBL4395583 | 0.83 | NPC1 (0.55) | TTBK1TTBK2EGFRERBB2RAB9A | |
| SCHEMBL3260635 | 0.83 | NPC1 (0.55) | TTBK1TTBK2EGFRRAB9ANPC1 | |
| SCHEMBL4345309 | 0.83 | EGFR (0.47) | TTBK1TTBK2EGFRERBB2RAB9A | |
| SCHEMBL4062637 | 0.82 | RAB9A (0.43) | TTBK1TTBK2EGFRERBB2RAB9A | |
| SCHEMBL12262450 | 0.81 | ALDH1A1 (0.53) | TTBK1TTBK2EGFRERBB2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | disclosed |
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
| EP-1689376-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | disclosed |
| WO-2005051366-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | RET, PRKDC, PRKACA | ALK 284/4885TTBK1 369/4885TTBK2 391/4885 |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | UCK2, PRKDC, PRKACA | ALK 1739/4885TTBK1 414/4885TTBK2 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.